

Integration of AI-Driven Design with Nanotechnology for Accelerated Drug Development

Dhanasekar Jayakumar*, Lathamani Lakshmanan, Snehal Dasharath Pawar, Nandhakumaran Subramanian

Department of Pharmaceutics, Vivekanandha Pharmacy College, Veerachipalayam, Sankari, Salem,

Corresponding author: jdhanasekar626@gmail.com

Doi: <https://doi.org/10.5281/zenodo.20037761>

Received: 19 May 2026

Accepted: 26 May 2026

Abstract:

Drug discovery and development is a complex, time-consuming, and costly process with high failure rates, necessitating innovative strategies to improve efficiency and success. In recent years, Artificial Intelligence (AI) has emerged as a transformative tool in pharmaceutical research, enabling rapid data analysis, predictive modeling, and intelligent decision-making across various stages of drug development. Simultaneously, nanotechnology has revolutionized drug delivery systems by enhancing solubility, stability, bioavailability, and targeted delivery of therapeutic agents through advanced nanocarriers such as polymeric nanoparticles, liposomes, and nanosuspensions. This review aims to explore the integration of AI-driven design approaches with nanotechnology to accelerate drug development. The synergistic combination of AI and nanotechnology offers significant advantages, including optimized formulation design, precise control over nanoparticle characteristics, improved prediction of drug loading and release profiles, and enhanced targeting efficiency. AI techniques such as machine learning and deep learning facilitate the rational design of nanocarriers, reducing experimental burden and enabling data-driven decision-making. The review highlights key applications of AI-integrated nanotechnology in cancer therapy, infectious disease management, personalized medicine, and gene delivery systems. Despite these advancements, challenges such as data limitations, model interpretability, regulatory barriers, and scalability remain critical concerns. The convergence of AI and nanotechnology represents a promising frontier in modern pharmaceutics, with the potential to significantly shorten development timelines, reduce costs, and improve therapeutic outcomes. Future research focusing on interdisciplinary collaboration and robust regulatory frameworks will be essential to translate these innovations into clinical practice.

Keywords: Artificial Intelligence, Nanotechnology, Drug Development, Machine Learning, Nanocarriers, Precision Medicine

1. Introduction

Traditional drug development is a complex, time-intensive, and costly process, typically requiring 10–15 years and substantial financial investment to bring a new therapeutic agent to market. The process involves multiple stages, including target identification, lead discovery, preclinical evaluation, and clinical trials. Despite these extensive efforts, the success rate remains low, with a high attrition rate due to safety concerns, lack of efficacy, and poor pharmacokinetic properties. These challenges highlight the limitations of conventional drug development strategies and the urgent need for more efficient and innovative approaches [1].

In recent years, Artificial Intelligence (AI) has emerged as a transformative tool in pharmaceutical research. AI techniques, including machine learning, deep learning, and neural networks, enable rapid analysis of large-scale biological and chemical datasets. These technologies facilitate drug target identification, virtual screening, lead optimization, and prediction of drug–target interactions with improved accuracy and reduced time. AI-driven approaches significantly enhance the efficiency of drug

discovery while lowering costs and improving success rates [2,3]. Parallel to AI advancements, nanotechnology has revolutionized drug delivery systems by offering improved solubility, stability, and bioavailability of therapeutic agents. Nanocarriers such as polymeric nanoparticles, liposomes, dendrimers, and nanosuspensions enable targeted and controlled drug delivery, thereby minimizing systemic toxicity and enhancing therapeutic efficacy. These nanoscale systems can overcome biological barriers and provide site-specific drug action, making them highly valuable in modern medicine [4].

Despite the individual advantages of AI and nanotechnology, their integration represents a powerful and emerging paradigm in drug development. AI can be applied to design and optimize nanocarriers, predict their physicochemical and biological behavior, and personalize drug delivery systems based on patient-specific data. This synergistic approach accelerates formulation development, improves precision in drug targeting, and enhances overall therapeutic outcomes [5]. The aim of this review is to explore the integration of AI-driven design with nanotechnology for accelerated drug development. This review focuses on recent advancements, key applications, benefits, and challenges of this interdisciplinary approach, while also highlighting future perspectives in the development of efficient, targeted, and personalized therapeutic systems.

2. Fundamentals of AI in drug development

Artificial Intelligence (AI) refers to the simulation of human intelligence in machines that are programmed to learn, reason, and make decisions. A key subset of AI is Machine Learning (ML), which enables systems to learn from data and improve performance without being explicitly programmed. In pharmaceutical research, AI and ML have become essential tools for handling large and complex biological datasets, enabling faster and more accurate drug development processes [6]. AI encompasses several important subfields, including Machine Learning (ML), Deep Learning (DL), and Natural Language Processing (NLP). Machine Learning involves the use of algorithms that identify patterns in data and make predictions or decisions. Deep Learning, a subset of ML, utilizes artificial neural networks with multiple layers to model complex relationships, particularly in image analysis, molecular modeling, and drug–target interactions. Natural Language Processing focuses on the analysis and interpretation of textual data, such as scientific literature, clinical reports, and patents, allowing researchers to extract valuable insights for drug discovery [7, 8].

AI technologies play a crucial role in various stages of drug development. One of the key applications is drug target identification, where AI algorithms analyze genomic, proteomic, and clinical data to identify potential biological targets associated with diseases. This significantly reduces the time required for early-stage discovery and improves target validation accuracy [6]. In addition, AI facilitates lead compound discovery through virtual screening of large chemical libraries. Machine learning models can predict the biological activity of compounds and identify promising drug candidates with higher precision compared to traditional screening methods. This approach reduces experimental workload and accelerates the identification of potential therapeutic molecules [7]. Furthermore, AI supports predictive modeling in drug development by forecasting pharmacokinetic properties, toxicity, and drug efficacy. These predictive models help in optimizing drug candidates before clinical trials, thereby minimizing failure rates and reducing development costs. AI-driven predictive analytics also enhance decision-making throughout the drug development pipeline [8].




Figure 1. Overview of Artificial Intelligence Applications in Drug Development

3. Overview of nanotechnology in pharmaceuticals

Nanotechnology refers to the design, development, and application of materials at the nanoscale range (1–100 nm), where unique physicochemical properties such as increased surface area, enhanced reactivity, and improved biological interactions can be achieved. In pharmaceuticals, nanotechnology plays a crucial role in improving drug delivery, diagnostics, and therapeutic efficacy by enabling precise control over drug release and targeting [9]. Various types of nanocarriers have been developed for pharmaceutical applications. Among them, polymeric nanoparticles are widely used due to their biocompatibility, biodegradability, and ability to provide controlled and sustained drug release. These systems can encapsulate both hydrophilic and hydrophobic drugs, enhancing their stability and therapeutic performance [10].

Liposomes are spherical vesicles composed of phospholipid bilayers that can encapsulate drugs within their aqueous core or lipid membrane. They are extensively used for targeted drug delivery due to their ability to reduce toxicity and improve drug accumulation at specific sites, particularly in cancer therapy [11]. Solid lipid nanoparticles (SLNs) are another important class of nanocarriers made from solid lipids. They offer advantages such as improved drug stability, controlled release, and protection of labile drugs from degradation. SLNs also exhibit good biocompatibility and are suitable for large-scale production [12]. Nanosuspensions are submicron colloidal dispersions of pure drug particles stabilized by surfactants or polymers. These systems are particularly useful for poorly water-soluble drugs, as they enhance dissolution rate, saturation solubility, and bioavailability [13]. Nanotechnology-based drug delivery systems offer several advantages over conventional formulations. These include improved solubility and bioavailability of poorly soluble drugs, targeted and site-specific drug delivery, controlled and sustained release profiles, reduced toxicity, and enhanced therapeutic efficacy. Additionally, nanocarriers can overcome biological barriers and improve drug stability, making them highly effective in modern pharmaceutical applications [9, 10].




Figure 2. Types of nanocarriers in pharmaceuticals

4. AI-driven design of nanocarriers

Artificial Intelligence (AI) has significantly advanced the design and development of nanocarriers by enabling data-driven and predictive formulation strategies. In pharmaceutical formulation design, AI algorithms can analyze complex datasets involving drug properties, excipients, and process parameters to identify optimal combinations for efficient nanocarrier systems. This reduces trial-and-error experimentation and accelerates formulation development [14]. AI also plays a crucial role in the optimization of nanoparticle size, shape, and surface properties, which are critical determinants of drug delivery performance. Machine learning models can predict how variations in formulation parameters affect particle size distribution, morphology, surface charge, and stability. Such optimization enhances cellular uptake, biodistribution, and targeting efficiency of nanocarriers [15].

Another important application of AI is the prediction of drug loading and release behavior. AI-based models can estimate drug encapsulation efficiency and simulate release kinetics under different physiological conditions. This allows researchers to design nanocarriers with controlled and sustained drug release profiles, improving therapeutic outcomes [16]. Several case studies from literature demonstrate the successful application of AI in nanocarrier design. For example, machine learning models have been used to optimize lipid nanoparticle formulations for drug and gene delivery, as well as to predict nanoparticle interactions with biological systems. These studies highlight the potential of AI to enhance precision and efficiency in nanomedicine development [14, 15].

5. Integration strategies

The integration of AI with nanotechnology has led to the development of advanced strategies for efficient drug delivery system design. One of the key approaches is AI-assisted formulation development, where computational models guide the selection of materials and process parameters to achieve desired formulation characteristics. This approach significantly reduces development time and experimental costs [16]. Data-driven nanomedicine design is another important strategy, where large datasets from experimental and clinical studies are used to train AI models. These models can identify patterns and relationships that are not easily detectable through conventional methods, enabling the development of more effective and personalized nanocarrier systems [17].

Computational modeling and simulation play a vital role in understanding nanoparticle behavior in biological systems. AI-enhanced simulations can predict pharmacokinetics, biodistribution, and toxicity of nanocarriers, thereby improving decision-making during drug development. These *in silico*

approaches reduce reliance on animal studies and accelerate translational research [18]. An emerging concept in pharmaceutical development is the use of digital twins, which are virtual replicas of drug formulations or biological systems. AI-driven digital twins allow real-time monitoring, simulation, and optimization of drug delivery systems, enabling continuous improvement and personalized treatment strategies. This approach represents a significant advancement toward precision medicine and smart pharmaceutical manufacturing [17, 18].




Figure 3. Comparison of AI-Assisted Formulation and Data-Driven Nanomedicine Approaches

6. Applications in drug development




Figure 4. Applications of artificial intelligence in drug delivery

6.1 Cancer Therapy

Artificial Intelligence (AI) has significantly enhanced cancer therapy by enabling the design of targeted nanocarriers that deliver anticancer drugs specifically to tumor tissues. AI algorithms optimize nanoparticle properties such as size, surface charge, and ligand attachment to improve tumor targeting and cellular uptake. These AI-driven nanocarriers enhance drug accumulation at the tumor site while minimizing off-target toxicity and adverse effects. Additionally, AI helps in predicting drug release kinetics and improving therapeutic outcomes in cancer treatment [19].

6.2 Infectious Diseases

In the field of infectious diseases, AI facilitates rapid drug screening by analyzing large chemical and biological datasets to identify potential antimicrobial agents. When integrated with nanotechnology, AI supports the development of advanced drug delivery systems that enhance drug stability, bioavailability, and targeted action against pathogens. This combined approach is particularly useful in addressing antimicrobial resistance and accelerating the discovery of novel therapeutics [20].

6.3 Personalized Medicine

AI plays a crucial role in advancing personalized medicine by enabling patient-specific drug formulation. By analyzing genetic, proteomic, and clinical data, AI can predict individual responses to drugs and assist in designing customized nanocarrier systems. These tailored drug delivery systems improve therapeutic efficacy, reduce adverse effects, and provide more precise treatment strategies based on patient-specific characteristics [21].

6.4 Gene and RNA Delivery

AI-driven design has also revolutionized gene and RNA delivery systems, including siRNA and mRNA-based therapies. AI models are used to optimize nanocarriers such as lipid nanoparticles for efficient delivery of genetic material into target cells. These optimized systems improve stability, cellular uptake, and targeted delivery, making them highly effective for gene therapy, gene editing, and vaccine development. This approach has gained significant importance in modern therapeutics, particularly in the development of advanced biologics [22].

7. Dvantages of AI–nanotech integration

The integration of Artificial Intelligence (AI) with nanotechnology offers significant advantages in drug development. One of the primary benefits is the reduction in development time, as AI-driven models can

rapidly analyze complex datasets and predict optimal formulations, thereby minimizing the need for extensive experimental trials. This accelerates the overall drug discovery and development process [23]. Another key advantage is cost efficiency, as AI reduces reliance on trial-and-error approaches and decreases the number of failed candidates in later stages. By optimizing formulation parameters early in development, significant financial resources can be saved [24].

AI also improves accuracy and predictive capabilities by utilizing advanced algorithms to forecast drug behavior, nanoparticle interactions, and therapeutic outcomes. These predictive models enhance decision-making and reduce uncertainties associated with drug development [23]. Furthermore, the integration enhances therapeutic efficacy by enabling the design of highly efficient nanocarriers with controlled drug release and improved bioavailability. AI helps tailor drug delivery systems to achieve optimal pharmacokinetic and pharmacodynamic profiles [25]. Additionally, AI-driven nanotechnology ensures better targeting and reduced side effects by designing nanocarriers that selectively deliver drugs to specific tissues or cells. This targeted approach minimizes systemic toxicity and improves patient safety, making treatments more effective and reliable [25].




Figure 5. Advantages of AI–nanotechnology integration in drug delivery

8. Challenges and limitations

Despite its advantages, the integration of AI and nanotechnology faces several challenges. One major limitation is data availability and quality, as AI models require large, high-quality datasets for accurate predictions. Incomplete or biased data can lead to unreliable outcomes and limit model performance [26]. Another challenge is model interpretability, as many AI algorithms, particularly deep learning models, function as “black boxes.” This lack of transparency makes it difficult for researchers and regulatory authorities to fully understand and trust the decision-making process [23]. Regulatory concerns also pose significant barriers, as there are currently limited standardized guidelines for the approval of AI-driven nanomedicine products. Regulatory agencies face challenges in evaluating the safety, efficacy, and reproducibility of such advanced systems [24].

In addition, scale-up and manufacturing issues remain critical, as translating laboratory-scale nanocarrier systems to large-scale industrial production can be complex and costly. Maintaining consistency, stability, and quality during large-scale production is a major hurdle [25]. Finally, ethical considerations must be addressed, including data privacy, algorithmic bias, and accountability in AI-driven decision-making.

Ensuring ethical use of AI in healthcare is essential for its successful implementation and public acceptance [26].

9. Recent advances

The rapid integration of artificial intelligence (AI) with nanotechnology has led to significant advancements in drug delivery and nanomedicine. Recent developments focus on the use of AI-driven platforms, big data analytics, gene-editing technologies, and smart nanosystems to enhance formulation design, precision targeting, and therapeutic efficiency. The following table summarizes key emerging trends and their applications in AI-assisted nanocarrier systems.

Table 1. Emerging trends and advancements in AI-integrated nanotechnology for drug delivery

S. No.	Area	Description	Reference
1	AI-based Nanocarrier Design Platforms	Advanced AI platforms are being developed to design and optimize nanocarriers by predicting physicochemical properties, drug loading capacity, and biological interactions. These platforms use machine learning algorithms to accelerate formulation development and improve precision in drug delivery system design.	[27]
2	Use of Big Data in Nanomedicine	The integration of big data analytics with nanomedicine enables the processing of large-scale biological, clinical, and formulation datasets. This helps in identifying patterns, improving predictive modeling, and supporting data-driven decision-making in drug development.	[28]
3	Integration with CRISPR and Gene Therapy	AI and nanotechnology are increasingly integrated with gene-editing technologies such as CRISPR to enhance gene delivery efficiency. Nanocarriers are optimized using AI to safely and effectively deliver gene-editing components to target cells, improving therapeutic outcomes.	[29]
4	Smart and Responsive Nanosystems	Smart nanosystems capable of responding to environmental stimuli such as pH, temperature, or enzymes are being developed using AI-driven design. These systems enable controlled and site-specific drug release, improving treatment efficiency and reducing side effects.	[30]

10. Future perspectives

The integration of Artificial Intelligence (AI) with nanotechnology is expected to play a transformative role in the future of drug development, particularly in the advancement of AI-driven personalized nanomedicine. By leveraging patient-specific data such as genomics, proteomics, and clinical profiles, AI can facilitate the design of customized nanocarrier systems tailored to individual therapeutic needs. This approach enhances treatment efficacy, minimizes adverse effects, and represents a significant step toward precision medicine [31]. Another important future direction is the clinical translation of AI-enabled nanomedicine. Although numerous preclinical studies have demonstrated promising results, translating these technologies into clinical practice remains a challenge. Future efforts will focus on improving the safety, scalability, and reproducibility of AI-designed nanocarriers to meet clinical and regulatory requirements. Enhanced collaboration between researchers, clinicians, and regulatory bodies will be essential to accelerate the clinical adoption of these advanced systems [32].

The implementation of automation in pharmaceutical research and development (R&D) is also expected to expand significantly. AI-driven automation, including robotic experimentation and high-throughput screening, can streamline drug discovery processes, reduce human error, and increase efficiency. Automated platforms integrated with AI can rapidly design, test, and optimize nanocarrier systems, thereby accelerating innovation and reducing development timelines [33]. Furthermore, the development of a robust regulatory framework is crucial for the successful integration of AI and nanotechnology in drug development. Regulatory agencies must establish clear guidelines and standards for evaluating the safety, efficacy, and quality of AI-driven nanomedicines. Addressing issues related to data transparency,

algorithm validation, and ethical considerations will be essential to ensure trust and widespread adoption of these technologies in healthcare [34].

11. Conclusion

The integration of Artificial Intelligence (AI) with nanotechnology represents a transformative advancement in modern drug development. By combining data-driven computational approaches with innovative nanoscale delivery systems, this interdisciplinary strategy effectively addresses the major limitations of traditional pharmaceutical research, including high cost, long development timelines, and low success rates. AI enhances the design and optimization of nanocarriers by enabling precise prediction of drug behavior, formulation parameters, and biological interactions. At the same time, nanotechnology improves drug delivery through targeted, controlled, and efficient transport of therapeutic agents, thereby increasing bioavailability and reducing systemic toxicity. Together, these technologies significantly improve the accuracy, efficiency, and success of drug development processes.

The applications of AI-integrated nanotechnology in areas such as cancer therapy, infectious diseases, personalized medicine, and gene delivery highlight its broad potential in addressing complex healthcare challenges. Furthermore, recent advancements such as smart nanosystems, big data integration, and AI-driven formulation platforms demonstrate the rapid evolution of this field. Despite these promising developments, challenges related to data quality, model interpretability, regulatory approval, and large-scale manufacturing must be addressed to ensure successful clinical translation. Ethical considerations and the development of standardized regulatory frameworks will also play a critical role in the widespread adoption of these technologies. Overall, the integration of AI and nanotechnology holds immense potential to revolutionize drug discovery and delivery. Continued interdisciplinary research, technological innovation, and collaborative efforts between academia, industry, and regulatory bodies are essential to fully realize its benefits. In the future, this synergistic approach is expected to pave the way for more efficient, targeted, and personalized therapeutic solutions, ultimately improving patient outcomes and transforming global healthcare.

12. References

1. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., et al. (2010). Improve R&D productivity: The pharmaceutical industry's grand challenge. *Nature Reviews Drug Discovery*, 9(3), 203–214.
2. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., et al. (2019). Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery*, 18(6), 463–477.
3. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., Blaschke, T. (2018). The rise of deep learning in drug discovery. *Drug Discovery Today*, 23(6), 1241–1250.
4. Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., et al. (2018). Nano-based drug delivery systems: Recent developments and future prospects. *Journal of Nanobiotechnology*, 16(1), 71.
5. Baptista, P. V., McCusker, M. P., Carvalho, A., Ferreira, D. A., Mohan, N. M., Martins, M., et al. (2021). Nano-strategies for molecular diagnostics and therapy: The role of nanotechnology in personalized medicine. *Journal of Nanobiotechnology*, 19(1), 1–46.
6. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., et al. (2019). Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery*, 18(6), 463–477.
7. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., Blaschke, T. (2018). The rise of deep learning in drug discovery. *Drug Discovery Today*, 23(6), 1241–1250.
8. Wang, Y., Kung, L., Byrd, T. A. (2018). Big data analytics: Understanding its capabilities and potential benefits for healthcare organizations. *Technological Forecasting and Social Change*, 126, 3–13.
9. Roco, M. C. (2003). Nanotechnology: Convergence with modern biology and medicine. *Current Opinion in Biotechnology*, 14(3), 337–346.
10. Kumari, A., Yadav, S. K., Yadav, S. C. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. *Colloids and Surfaces B: Biointerfaces*, 75(1), 1–18.
11. Bozzuto, G., Molinari, A. (2015). Liposomes as nanomedical devices. *International Journal of Nanomedicine*, 10, 975–999.

12. Mehnert, W., Mäder, K. (2001). Solid lipid nanoparticles: Production, characterization and applications. *Advanced Drug Delivery Reviews*, 47(2–3), 165–196.
13. Müller, R. H., Jacobs, C., Kayser, O. (2001). Nanosuspensions as particulate drug formulations in therapy. *Advanced Drug Delivery Reviews*, 47(1), 3–19.
14. Ciallella, H. L., et al. (2021). Artificial intelligence and machine learning in nanomedicine: Opportunities and challenges. *Advanced Drug Delivery Reviews*, 171, 143–160.
15. He, H., et al. (2020). Machine learning in nanoparticle design for drug delivery. *ACS Nano*, 14(12), 16469–16481.
16. Bannigan, P., Aldeghi, M., Bao, Z., Häse, F., Aspuru-Guzik, A. (2021). Machine learning directed drug formulation development. *Advanced Drug Delivery Reviews*, 175, 113806.
17. Rai, R., et al. (2021). Data-driven nanomedicine: Role of artificial intelligence in drug delivery. *Nanomedicine*, 16(1), 85–101.
18. Viceconti, M., Henney, A., Morley-Fletcher, E. (2016). In silico clinical trials: How computer simulation will transform the biomedical industry. *International Journal of Clinical Trials*, 3(2), 37–46.
19. He, H., et al. (2020). Machine learning in nanoparticle design for drug delivery. *ACS Nano*, 14(12), 16469–16481.
20. Stokes, J. M., et al. (2020). A deep learning approach to antibiotic discovery. *Cell*, 180(4), 688–702.e13.
21. Ashley, E. A. (2015). The precision medicine initiative: A new national effort. *JAMA*, 313(21), 2119–2120.
22. Hou, X., et al. (2021). Lipid nanoparticles for mRNA delivery. *Nature Reviews Materials*, 6(12), 1078–1094.
23. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., et al. (2019). Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery*, 18(6), 463–477.
24. Bannigan, P., Aldeghi, M., Bao, Z., Häse, F., Aspuru-Guzik, A. (2021). Machine learning directed drug formulation development. *Advanced Drug Delivery Reviews*, 175, 113806.
25. Ciallella, H. L., et al. (2021). Artificial intelligence and machine learning in nanomedicine: Opportunities and challenges. *Advanced Drug Delivery Reviews*, 171, 143–160.
26. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. *Nature Medicine*, 25(1), 44–56.
27. He, H., et al. (2020). Machine learning in nanoparticle design for drug delivery. *ACS Nano*, 14(12), 16469–16481.
28. Wang, Y., Kung, L., Byrd, T. A. (2018). Big data analytics: Understanding its capabilities and potential benefits for healthcare organizations. *Technological Forecasting and Social Change*, 126, 3–13.
29. Doudna, J. A., Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. *Science*, 346(6213), 1258096.
30. Mura, S., Nicolas, J., Couvreur, P. (2013). Stimuli-responsive nanocarriers for drug delivery. *Nature Materials*, 12(11), 991–1003.
31. Ashley, E. A. (2015). The precision medicine initiative: A new national effort. *JAMA*, 313(21), 2119–2120.
32. Etheridge, M. L., Campbell, S. A., Erdman, A. G., Haynes, C. L., Wolf, S. M., McCullough, J. (2013). The big picture on nanomedicine: The state of investigational and approved nanomedicine products. *Nanomedicine*, 9(1), 1–14.
33. Schneider, G. (2018). Automating drug discovery. *Nature Reviews Drug Discovery*.